The American College of Physicians has released new recommendations in favor of SGLT2i and GLP-1 RA and against the use of DPP-4i as second-line therapies to metformin in adults with type 2 diabetes and inadequate glycemic control. Released on the first day of the ACP’s Internal Medicine Meeting 2024, the pair of recommendations reflect the findings from a systematic review and network meta-analysis and cost-effectiveness analysis assessing the value of these therapies as both monotherapies and in combination with metformin.

Attendees at this year’s meeting, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ACP’s latest recommendations in a special ACP 2024 edition of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives.

Video Version: https://www.hcplive.com/view/diabetes-dialogue-2024-acp-type-2-diabetes-recommendations